Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001178913-25-001505
Filing Date
2025-04-29
Accepted
2025-04-29 12:10:45
Documents
20

Document Format Files

Seq Description Document Type Size
1 424B3 zk2533099.htm 424B3 2279344
2 image00002.jpg GRAPHIC 4874
3 image00003.jpg GRAPHIC 42669
4 image00004.jpg GRAPHIC 6920
5 image00005.jpg GRAPHIC 25363
6 image00006.jpg GRAPHIC 29106
7 image00007.jpg GRAPHIC 30682
8 image00008.jpg GRAPHIC 35405
9 image00009.jpg GRAPHIC 28423
10 image00010.jpg GRAPHIC 25007
11 image00011.jpg GRAPHIC 28185
12 image00012.jpg GRAPHIC 23780
13 image00013.jpg GRAPHIC 38848
14 image00014.jpg GRAPHIC 29274
15 image00015.jpg GRAPHIC 27487
16 image00016.jpg GRAPHIC 22931
17 image00017.jpg GRAPHIC 26551
18 image00018.jpg GRAPHIC 21649
19 image00019.jpg GRAPHIC 19778
20 image00020.jpg GRAPHIC 2568
  Complete submission text file 0001178913-25-001505.txt   2929122
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-282932 | Film No.: 25884611
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)